ID   PDCD6_HUMAN             Reviewed;         191 AA.
AC   O75340; B2RD16; E7ESR3; Q2YDC2; Q5TZS0;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   22-JUL-2015, entry version 147.
DE   RecName: Full=Programmed cell death protein 6;
DE   AltName: Full=Apoptosis-linked gene 2 protein;
DE   AltName: Full=Probable calcium-binding protein ALG-2;
GN   Name=PDCD6; Synonyms=ALG2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Ganjei J.K., D'Adamio L.;
RL   Submitted (NOV-1997) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RA   Urcelay E., Ibarreta D., Parrilla R., Ayuso M.S.;
RL   Submitted (MAY-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Colon, Ovary, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH PEF1.
RX   PubMed=11278427; DOI=10.1074/jbc.M008649200;
RA   Kitaura Y., Matsumoto S., Satoh H., Hitomi K., Maki M.;
RT   "Peflin and ALG-2, members of the penta-EF-hand protein family, form a
RT   heterodimer that dissociates in a Ca2+-dependent manner.";
RL   J. Biol. Chem. 276:14053-14058(2001).
RN   [9]
RP   INTERACTION WITH PEF1.
RX   PubMed=11883899; DOI=10.1006/abbi.2001.2736;
RA   Kitaura Y., Satoh H., Takahashi H., Shibata H., Maki M.;
RT   "Both ALG-2 and peflin, penta-EF-hand (PEF) proteins, are stabilized
RT   by dimerization through their fifth EF-hand regions.";
RL   Arch. Biochem. Biophys. 399:12-18(2002).
RN   [10]
RP   INTERACTION WITH ANXA11.
RX   PubMed=11883939; DOI=10.1006/bbrc.2002.6600;
RA   Satoh H., Shibata H., Nakano Y., Kitaura Y., Maki M.;
RT   "ALG-2 interacts with the amino-terminal domain of annexin XI in a
RT   Ca(2+)-dependent manner.";
RL   Biochem. Biophys. Res. Commun. 291:1166-1172(2002).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH DAPK1.
RX   PubMed=16132846; DOI=10.1007/s10529-005-7869-x;
RA   Lee J.H., Rho S.B., Chun T.;
RT   "Programmed cell death 6 (PDCD6) protein interacts with death-
RT   associated protein kinase 1 (DAPk1): additive effect on apoptosis via
RT   caspase-3 dependent pathway.";
RL   Biotechnol. Lett. 27:1011-1015(2005).
RN   [12]
RP   INTERACTION WITH RBM22.
RX   PubMed=17045351; DOI=10.1016/j.bbamcr.2006.09.003;
RA   Montaville P., Dai Y., Cheung C.Y., Giller K., Becker S., Michalak M.,
RA   Webb S.E., Miller A.L., Krebs J.;
RT   "Nuclear translocation of the calcium-binding protein ALG-2 induced by
RT   the RNA-binding protein RBM22.";
RL   Biochim. Biophys. Acta 1763:1335-1343(2006).
RN   [13]
RP   INTERACTION WITH SEC31A AND PDCD6IP, MUTAGENESIS OF GLU-47 AND
RP   GLU-114, AND SUBCELLULAR LOCATION.
RX   PubMed=16957052; DOI=10.1091/mbc.E06-05-0444;
RA   Yamasaki A., Tani K., Yamamoto A., Kitamura N., Komada M.;
RT   "The Ca2+-binding protein ALG-2 is recruited to endoplasmic reticulum
RT   exit sites by Sec31A and stabilizes the localization of Sec31A.";
RL   Mol. Biol. Cell 17:4876-4887(2006).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH WITH SHISA5.
RX   PubMed=17889823; DOI=10.1016/j.abb.2007.07.028;
RA   Draeby I., Woods Y.L., la Cour J.M., Mollerup J., Bourdon J.C.,
RA   Berchtold M.W.;
RT   "The calcium binding protein ALG-2 binds and stabilizes Scotin, a p53-
RT   inducible gene product localized at the endoplasmic reticulum
RT   membrane.";
RL   Arch. Biochem. Biophys. 467:87-94(2007).
RN   [15]
RP   INTERACTION WITH PLSCR3; PLSCR4; PDCD6IP; ANXA7; ANXA11; SEC31A AND
RP   TSG101, AND MUTAGENESIS OF GLU-47; TRP-57; PHE-60; TYR-91; TRP-95;
RP   GLU-114 AND TYR-180.
RX   PubMed=18256029; DOI=10.1074/jbc.M800717200;
RA   Shibata H., Suzuki H., Kakiuchi T., Inuzuka T., Yoshida H., Mizuno T.,
RA   Maki M.;
RT   "Identification of Alix-type and non-Alix-type ALG-2-binding sites in
RT   human phospholipid scramblase 3: differential binding to an
RT   alternatively spliced isoform and amino acid-substituted mutants.";
RL   J. Biol. Chem. 283:9623-9632(2008).
RN   [16]
RP   FUNCTION.
RX   PubMed=19520058; DOI=10.1016/j.bbrc.2009.06.015;
RA   Okumura M., Ichioka F., Kobayashi R., Suzuki H., Yoshida H.,
RA   Shibata H., Maki M.;
RT   "Penta-EF-hand protein ALG-2 functions as a Ca2+-dependent adaptor
RT   that bridges Alix and TSG101.";
RL   Biochem. Biophys. Res. Commun. 386:237-241(2009).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH MCOLN1.
RX   PubMed=19864416; DOI=10.1074/jbc.M109.047241;
RA   Vergarajauregui S., Martina J.A., Puertollano R.;
RT   "Identification of the penta-EF-hand protein ALG-2 as a Ca2+-dependent
RT   interactor of mucolipin-1.";
RL   J. Biol. Chem. 284:36357-36366(2009).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21122810; DOI=10.1016/j.bbamcr.2010.11.010;
RA   Janowicz A., Michalak M., Krebs J.;
RT   "Stress induced subcellular distribution of ALG-2, RBM22 and hSlu7.";
RL   Biochim. Biophys. Acta 1813:1045-1049(2011).
RN   [20]
RP   FUNCTION, AND INTERACTION WITH KDR.
RX   PubMed=21893193; DOI=10.1016/j.cellsig.2011.08.013;
RA   Rho S.B., Song Y.J., Lim M.C., Lee S.H., Kim B.R., Park S.Y.;
RT   "Programmed cell death 6 (PDCD6) inhibits angiogenesis through
RT   PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2.";
RL   Cell. Signal. 24:131-139(2012).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 24-191 IN COMPLEXES WITH
RP   CALCIUM; ZINC AND PDCD6IP, SUBUNIT, AND INTERACTION WITH PDCD6IP.
RX   PubMed=18940611; DOI=10.1016/j.str.2008.07.012;
RA   Suzuki H., Kawasaki M., Inuzuka T., Okumura M., Kakiuchi T.,
RA   Shibata H., Wakatsuki S., Maki M.;
RT   "Structural basis for Ca2+ -dependent formation of ALG-2/Alix peptide
RT   complex: Ca2+/EF3-driven arginine switch mechanism.";
RL   Structure 16:1562-1573(2008).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 24-191, INTERACTION WITH
RP   PDCD6IP; TSG101; ANXA7 AND ANXA11, AND MUTAGENESIS OF PHE-122.
RX   PubMed=20691033; DOI=10.1186/1472-6807-10-25;
RA   Inuzuka T., Suzuki H., Kawasaki M., Shibata H., Wakatsuki S., Maki M.;
RT   "Molecular basis for defect in Alix-binding by alternatively spliced
RT   isoform of ALG-2 (ALG-2DeltaGF122) and structural roles of F122 in
RT   target recognition.";
RL   BMC Struct. Biol. 10:25-25(2010).
RN   [24]
RP   VARIANT [LARGE SCALE ANALYSIS] CYS-123.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Calcium-binding protein required for T-cell receptor-,
CC       Fas-, and glucocorticoid-induced cell death. May mediate Ca(2+)-
CC       regulated signals along the death pathway (By similarity).
CC       Calcium-dependent adapter necessary for the association between
CC       PDCD6IP and TSG101. Interaction with DAPK1 can accelerate
CC       apoptotic cell death by increasing caspase-3 activity. May inhibit
CC       KDR/VEGFR2-dependent angiogenesis; the function involves
CC       inhibition of VEGF-induced phosphoprylation of the Akt signaling
CC       pathway. Seems to play a role in the regulation of the
CC       distribution and function of MCOLN1 in the endosomal pathway.
CC       Isoform 2 has a lower Ca(2+) affinity than isoform 1. Isoform 1
CC       and, to a lesser extend, isoform 2, can stabilize SHISA5.
CC       {ECO:0000250, ECO:0000269|PubMed:16132846,
CC       ECO:0000269|PubMed:17889823, ECO:0000269|PubMed:19520058,
CC       ECO:0000269|PubMed:19864416, ECO:0000269|PubMed:21893193}.
CC   -!- SUBUNIT: Isoform 1 and isoform 2 self-associate; probably forming
CC       homodimers. Interacts with SHISA5, PEF1, RBM22, PLSCR4, ANXA7,
CC       TSG101 and DAPK1. Interacts with PDCD6IP, SEC31A, ANXA11 (via N-
CC       terminus), PLSCR3 (via N-terminus) and MCOLN1; the interactions
CC       are calcium-dependent. Isoform 2 does not interact with SHISA5,
CC       PDCD6IP, TSG101, ANXA7 and ANXA11. {ECO:0000269|PubMed:11278427,
CC       ECO:0000269|PubMed:11883899, ECO:0000269|PubMed:11883939,
CC       ECO:0000269|PubMed:16132846, ECO:0000269|PubMed:16957052,
CC       ECO:0000269|PubMed:17045351, ECO:0000269|PubMed:17889823,
CC       ECO:0000269|PubMed:18256029, ECO:0000269|PubMed:18940611,
CC       ECO:0000269|PubMed:19864416, ECO:0000269|PubMed:20691033,
CC       ECO:0000269|PubMed:21893193}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-352915, EBI-352915;
CC       Q5T0G8:ANXA11; NbExp=3; IntAct=EBI-352915, EBI-10245225;
CC       P53355:DAPK1; NbExp=3; IntAct=EBI-352915, EBI-358616;
CC       Q9Y5Z4:HEBP2; NbExp=4; IntAct=EBI-352915, EBI-741593;
CC       P35968:KDR; NbExp=4; IntAct=EBI-352915, EBI-1005487;
CC       Q8WUM4:PDCD6IP; NbExp=5; IntAct=EBI-352915, EBI-310624;
CC       Q9UBV8:PEF1; NbExp=7; IntAct=EBI-352915, EBI-724639;
CC       Q9NRY6:PLSCR3; NbExp=9; IntAct=EBI-352915, EBI-750734;
CC       Q9H3S7:PTPN23; NbExp=3; IntAct=EBI-352915, EBI-724478;
CC       O94979:SEC31A; NbExp=6; IntAct=EBI-352915, EBI-1767898;
CC       A5D8V6:VPS37C; NbExp=3; IntAct=EBI-352915, EBI-2559305;
CC   -!- SUBCELLULAR LOCATION: Nucleus membrane; Peripheral membrane
CC       protein. Endoplasmic reticulum membrane; Peripheral membrane
CC       protein. Nucleus. Endosome. Note=Interaction with RBM22 induces
CC       relocalization from the cytoplasm to the nucleus. Translocated
CC       from the cytoplasm to the nucleus after heat shock cell treatment.
CC       Accumulates in cytoplasmic vesicle-like organelles after heat
CC       shock treatment, which may represent stress granules.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O75340-1; Sequence=Displayed;
CC       Name=2; Synonyms=ALG-2(delta)GF122;
CC         IsoId=O75340-2; Sequence=VSP_045113;
CC       Name=3;
CC         IsoId=O75340-3; Sequence=VSP_045542;
CC         Note=No experimental confirmation available.;
CC   -!- SIMILARITY: Contains 5 EF-hand domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00448}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PDCD6ID43402ch5p15.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF035606; AAC27697.1; -; mRNA.
DR   EMBL; U58773; AAF14336.1; -; mRNA.
DR   EMBL; AK315370; BAG37763.1; -; mRNA.
DR   EMBL; BT020072; AAV38875.1; -; mRNA.
DR   EMBL; AC010442; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC021087; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC118458; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471235; EAW50991.1; -; Genomic_DNA.
DR   EMBL; BC012384; AAH12384.1; -; mRNA.
DR   EMBL; BC106706; AAI06707.1; -; mRNA.
DR   EMBL; BC110291; AAI10292.1; -; mRNA.
DR   EMBL; CB991882; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS3854.1; -. [O75340-1]
DR   CCDS; CCDS58940.1; -. [O75340-2]
DR   CCDS; CCDS58941.1; -. [O75340-3]
DR   RefSeq; NP_001254485.1; NM_001267556.1. [O75340-2]
DR   RefSeq; NP_001254486.1; NM_001267557.1.
DR   RefSeq; NP_001254487.1; NM_001267558.1.
DR   RefSeq; NP_001254488.1; NM_001267559.1. [O75340-3]
DR   RefSeq; NP_037364.1; NM_013232.3. [O75340-1]
DR   UniGene; Hs.50823; -.
DR   PDB; 2ZN8; X-ray; 2.70 A; A=2-191.
DR   PDB; 2ZN9; X-ray; 2.40 A; A/B=20-191.
DR   PDB; 2ZND; X-ray; 1.70 A; A=20-191.
DR   PDB; 2ZNE; X-ray; 2.20 A; A/B=24-191.
DR   PDB; 2ZRS; X-ray; 3.10 A; A/B/C/D/E/F/G/H=24-191.
DR   PDB; 2ZRT; X-ray; 3.30 A; A/B/C/D/E/F/G/H=24-191.
DR   PDB; 3AAJ; X-ray; 2.40 A; A/B=24-191.
DR   PDB; 3AAK; X-ray; 2.70 A; A=20-191.
DR   PDB; 3WXA; X-ray; 2.36 A; A/B=20-191.
DR   PDBsum; 2ZN8; -.
DR   PDBsum; 2ZN9; -.
DR   PDBsum; 2ZND; -.
DR   PDBsum; 2ZNE; -.
DR   PDBsum; 2ZRS; -.
DR   PDBsum; 2ZRT; -.
DR   PDBsum; 3AAJ; -.
DR   PDBsum; 3AAK; -.
DR   PDBsum; 3WXA; -.
DR   ProteinModelPortal; O75340; -.
DR   SMR; O75340; 24-191.
DR   BioGrid; 115333; 40.
DR   DIP; DIP-33217N; -.
DR   IntAct; O75340; 32.
DR   MINT; MINT-5000341; -.
DR   STRING; 9606.ENSP00000264933; -.
DR   PhosphoSite; O75340; -.
DR   BioMuta; PDCD6; -.
DR   MaxQB; O75340; -.
DR   PRIDE; O75340; -.
DR   DNASU; 10016; -.
DR   Ensembl; ENST00000264933; ENSP00000264933; ENSG00000249915.
DR   Ensembl; ENST00000505221; ENSP00000422085; ENSG00000249915. [O75340-3]
DR   Ensembl; ENST00000507528; ENSP00000423815; ENSG00000249915. [O75340-2]
DR   GeneID; 10016; -.
DR   KEGG; hsa:10016; -.
DR   UCSC; uc003jat.1; human. [O75340-1]
DR   UCSC; uc003jau.2; human.
DR   CTD; 10016; -.
DR   GeneCards; GC05P000258; -.
DR   HGNC; HGNC:8765; PDCD6.
DR   MIM; 601057; gene.
DR   neXtProt; NX_O75340; -.
DR   PharmGKB; PA33115; -.
DR   GeneTree; ENSGT00620000087734; -.
DR   HOGENOM; HOG000231984; -.
DR   HOVERGEN; HBG004492; -.
DR   InParanoid; O75340; -.
DR   OMA; CVVIKQI; -.
DR   OrthoDB; EOG7RV9FM; -.
DR   PhylomeDB; O75340; -.
DR   TreeFam; TF314682; -.
DR   ChiTaRS; PDCD6; human.
DR   EvolutionaryTrace; O75340; -.
DR   GeneWiki; PDCD6; -.
DR   GenomeRNAi; 10016; -.
DR   NextBio; 37841; -.
DR   PRO; PR:O75340; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; O75340; -.
DR   CleanEx; HS_ALG2; -.
DR   CleanEx; HS_PDCD6; -.
DR   ExpressionAtlas; O75340; baseline and differential.
DR   Genevisible; O75340; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0070971; C:endoplasmic reticulum exit site; IMP:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031965; C:nuclear membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0060090; F:binding, bridging; IMP:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; ISS:UniProtKB.
DR   GO; GO:0004198; F:calcium-dependent cysteine-type endopeptidase activity; IBA:GO_Central.
DR   GO; GO:0048306; F:calcium-dependent protein binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0043495; F:protein anchor; IMP:UniProtKB.
DR   GO; GO:0046983; F:protein dimerization activity; IPI:UniProtKB.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0097190; P:apoptotic signaling pathway; TAS:ProtInc.
DR   GO; GO:0034605; P:cellular response to heat; IDA:UniProtKB.
DR   GO; GO:0006886; P:intracellular protein transport; IDA:UniProtKB.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0032007; P:negative regulation of TOR signaling; IDA:UniProtKB.
DR   GO; GO:0030948; P:negative regulation of vascular endothelial growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IDA:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0006508; P:proteolysis; IBA:GO_Central.
DR   GO; GO:0051592; P:response to calcium ion; ISS:UniProtKB.
DR   GO; GO:0036324; P:vascular endothelial growth factor receptor-2 signaling pathway; IDA:UniProtKB.
DR   Gene3D; 1.10.238.10; -; 1.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR018247; EF_Hand_1_Ca_BS.
DR   InterPro; IPR002048; EF_hand_dom.
DR   Pfam; PF13499; EF-hand_7; 1.
DR   SMART; SM00054; EFh; 5.
DR   PROSITE; PS00018; EF_HAND_1; 2.
DR   PROSITE; PS50222; EF_HAND_2; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Angiogenesis;
KW   Apoptosis; Calcium; Complete proteome; Endoplasmic reticulum;
KW   Endosome; Membrane; Metal-binding; Nucleus; Polymorphism;
KW   Reference proteome; Repeat.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:22223895}.
FT   CHAIN         2    191       Programmed cell death protein 6.
FT                                /FTId=PRO_0000073729.
FT   DOMAIN       23     58       EF-hand 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   DOMAIN       59     89       EF-hand 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   DOMAIN       90    125       EF-hand 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   DOMAIN      126    161       EF-hand 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   DOMAIN      162    191       EF-hand 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   CA_BIND      36     47       1.
FT   CA_BIND      73     84       2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   CA_BIND     103    114       3.
FT   CA_BIND     169    181       4.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000269|PubMed:22223895}.
FT   VAR_SEQ      70    191       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_045542.
FT   VAR_SEQ     121    122       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_045113.
FT   VARIANT     123    123       G -> C (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035459.
FT   MUTAGEN      47     47       E->A: Loss of interaction with SEC31A and
FT                                PLSCR3, and loss of localization to the
FT                                endoplasmic reticulum; when associated
FT                                with A-114. {ECO:0000269|PubMed:16957052,
FT                                ECO:0000269|PubMed:18256029}.
FT   MUTAGEN      57     57       W->A: Reduces the interaction with
FT                                PDCD6IP and ANXA7.
FT                                {ECO:0000269|PubMed:18256029}.
FT   MUTAGEN      60     60       F->A: Abolishes the interaction with
FT                                PDCD6IP, ANXA7 and ANXA11.
FT                                {ECO:0000269|PubMed:18256029}.
FT   MUTAGEN      91     91       Y->A: Abolishes the interaction with
FT                                PDCD6IP, ANXA7 and ANXA11.
FT                                {ECO:0000269|PubMed:18256029}.
FT   MUTAGEN      95     95       W->A: Abolishes the interaction with
FT                                PDCD6IP, ANXA7 and ANXA11.
FT                                {ECO:0000269|PubMed:18256029}.
FT   MUTAGEN     114    114       E->A: Loss of interaction with SEC31A and
FT                                PLSCR3, and loss of localization to the
FT                                endoplasmic reticulum; when associated
FT                                with A-47. {ECO:0000269|PubMed:16957052,
FT                                ECO:0000269|PubMed:18256029}.
FT   MUTAGEN     122    122       F->A: Increases interaction with PDCD6IP
FT                                and ANXA7. Impairs interaction with
FT                                ANXA11. Augments stauroporine-induced
FT                                cell death.
FT                                {ECO:0000269|PubMed:20691033}.
FT   MUTAGEN     122    122       F->G: Increases interaction with PDCD6IP.
FT                                Impairs interaction with ANXA11.
FT                                {ECO:0000269|PubMed:20691033}.
FT   MUTAGEN     122    122       F->S: Increases interaction with PDCD6IP.
FT                                Impairs interaction with ANAX7 and
FT                                ANXA11. {ECO:0000269|PubMed:20691033}.
FT   MUTAGEN     122    122       F->W: Impairs interaction with ANXA11.
FT                                {ECO:0000269|PubMed:20691033}.
FT   MUTAGEN     180    180       Y->A: Abolishes the interaction with
FT                                PDCD6IP, TSG101, ANXA7 and ANXA11.
FT                                {ECO:0000269|PubMed:18256029}.
FT   HELIX        26     35       {ECO:0000244|PDB:2ZND}.
FT   STRAND       36     40       {ECO:0000244|PDB:2ZRT}.
FT   STRAND       41     43       {ECO:0000244|PDB:2ZNE}.
FT   HELIX        45     51       {ECO:0000244|PDB:2ZND}.
FT   STRAND       55     58       {ECO:0000244|PDB:2ZND}.
FT   HELIX        62     72       {ECO:0000244|PDB:2ZND}.
FT   STRAND       74     80       {ECO:0000244|PDB:2ZND}.
FT   HELIX        82    102       {ECO:0000244|PDB:2ZND}.
FT   STRAND      107    110       {ECO:0000244|PDB:2ZND}.
FT   HELIX       112    121       {ECO:0000244|PDB:2ZND}.
FT   HELIX       128    138       {ECO:0000244|PDB:2ZND}.
FT   STRAND      143    147       {ECO:0000244|PDB:2ZND}.
FT   HELIX       148    168       {ECO:0000244|PDB:2ZND}.
FT   STRAND      172    174       {ECO:0000244|PDB:2ZND}.
FT   HELIX       180    188       {ECO:0000244|PDB:2ZND}.
SQ   SEQUENCE   191 AA;  21868 MW;  D0B5944CF3C696AD CRC64;
     MAAYSYRPGP GAGPGPAAGA ALPDQSFLWN VFQRVDKDRS GVISDTELQQ ALSNGTWTPF
     NPVTVRSIIS MFDRENKAGV NFSEFTGVWK YITDWQNVFR TYDRDNSGMI DKNELKQALS
     GFGYRLSDQF HDILIRKFDR QGRGQIAFDD FIQGCIVLQR LTDIFRRYDT DQDGWIQVSY
     EQYLSMVFSI V
//
